↓ Skip to main content

Epigenetic inactivation of the candidate 3p21.3 suppressor gene BLU in human cancers

Overview of attention for article published in Oncogene, March 2003
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (71st percentile)
  • Above-average Attention Score compared to outputs of the same age and source (57th percentile)

Mentioned by

patent
6 patents
wikipedia
3 Wikipedia pages

Citations

dimensions_citation
89 Dimensions

Readers on

mendeley
24 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Epigenetic inactivation of the candidate 3p21.3 suppressor gene BLU in human cancers
Published in
Oncogene, March 2003
DOI 10.1038/sj.onc.1206243
Pubmed ID
Authors

Angelo Agathanggelou, Ashraf Dallol, Sabine Zöchbauer-Müller, Catherine Morrissey, Sofia Honorio, Luke Hesson, Tommy Martinsson, Kwun M Fong, Michael J Kuo, Po Wing Yuen, Eamonn R Maher, John D Minna, Farida Latif

Abstract

Many distinct regions of 3p show frequent allelic losses in a wide range of tumour types. Previously, the BLU candidate tumour suppressor gene (TSG) encoded by a gene-rich critical deleted region in 3p21.3 was found to be inactivated rarely in lung cancer, although expression was downregulated in a subset of lung tumour cell lines. To elucidate the role of BLU in tumorigenesis, we analysed BLU promoter methylation status in tumour cell lines and detected promoter region hypermethylation in 39% lung, 42% breast, 50% kidney, 86% neuroblastoma and 80% nasopharyngeal (NPC) tumour cell lines. Methylation of the BLU promoter region correlated with the downregulation of BLU transcript expression in tumour cell lines. Expression was recovered in tumour cell lines treated with 5-aza 2-deoxycytidine. Exogenous expression of BLU in neuroblastoma (SK-N-SH) and NSCLC (NCI-H1299) resulted in reduced colony formation efficiency, in vitro. Furthermore, methylation of the BLU promoter region was detected in primary sporadic SCLC (14%), NSCLC (19%) and neuroblastoma (41%). As frequent methylation of the RASSF1A 3p21.3 TSG has also been reported in these tumour types, we investigated whether BLU and RASSF1A methylation were independent or related events. No correlation was found between hypermethylation of RASSF1A and BLU promoter region CpG islands in SCLC or neuroblastoma. However, there was association between RASSF1A and BLU methylation in NSCLC (P=0.0031). Our data suggest that in SCLC and neuroblastoma, RASSF1A and BLU methylations are unrelated events and not a manifestation of a regional alteration in epigenetic status, while in NSCLC there may be a regional methylation effect. Together, these data suggest a significant role for epigenetic inactivation of BLU in the pathogenesis of common human cancers and that methylation inactivation of BLU occurs independent of RASSF1A in SCLC and neuroblastoma tumours.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 24 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Belgium 2 8%
Unknown 22 92%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 4 17%
Researcher 4 17%
Student > Bachelor 4 17%
Student > Master 2 8%
Student > Doctoral Student 1 4%
Other 5 21%
Unknown 4 17%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 8 33%
Agricultural and Biological Sciences 5 21%
Medicine and Dentistry 3 13%
Nursing and Health Professions 1 4%
Psychology 1 4%
Other 1 4%
Unknown 5 21%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 July 2022.
All research outputs
#4,744,868
of 22,979,862 outputs
Outputs from Oncogene
#2,298
of 10,672 outputs
Outputs of similar age
#8,406
of 49,248 outputs
Outputs of similar age from Oncogene
#12
of 101 outputs
Altmetric has tracked 22,979,862 research outputs across all sources so far. Compared to these this one has done well and is in the 76th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 10,672 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.1. This one has gotten more attention than average, scoring higher than 67% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 49,248 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.
We're also able to compare this research output to 101 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 57% of its contemporaries.